Outcome of proficiency test on EIA serology

Similar documents
Cross Border Genetic Testing for Rare Diseases

Smokefree Policies in Europe: Are we there yet?

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 SERBIA

Overview of drug-induced deaths in Europe - What does the data tell us?

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

REVIEW OF THE ANALYSIS RELATED TO RABIES DIAGNOSIS AND FOLLOW-UP OF ORAL VACCINATION PERFORMED IN NRLS IN 2015

LEBANON. WCPT COUNTRY PROFILE December 2018

DENMARK. WCPT COUNTRY PROFILE December 2018

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Monthly measles and rubella monitoring report

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

GERMANY. WCPT COUNTRY PROFILE December 2018

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

Where we stand in EFORT

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

Engagement in language assessment / Regions of Europe

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

A European Union-wide slaughterhouse baseline survey on the prevalence of Salmonella in slaughter pigs

European Collaboration on Dementia. Luxembourg, 13 December 2006

Where do EU Contries set the limit for low risk drinking.

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Alcohol-related harm in Europe and the WHO policy response

The Risk of Alcohol in Europe. Bridging the Gap June 2004

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

Q1 What age are you?

European Community Pharmacy: a reference in Public Health

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

The health economic landscape of cancer in Europe

Underage drinking in Europe

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

The cancer burden in the European Union and the European Region: the current situation and a way forward

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Rheumatoid Arthritis Disease Burden and Access to Treatment

The Identification of Food Safety Priorities using the Delphi Technique

real-time AQ data 2007 and plans for 2008

Measles and rubella monitoring January 2015

Project Meeting Prague

Nutrient profiles for foods bearing claims

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Transmission, processing and publication of HBS 2015 data

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Critical immunity thresholds for measles elimination

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

European Status report on Alcohol and Health

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

This document is a preview generated by EVS

Real Life, Real PD Survey

European status report on alcohol and health Leadership, awareness and commitment

CNAPA Meeting Luxembourg September 2016

SOITC Press Ad FAQs. Q: When will these Terms and Conditions changes come into effect?

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Correction to: The education gradient in cancer screening participation: a consistent phenomenon across Europe?

Extrapolation and potential impact of IPHS deployment in Europe

Perspectives for information on alcohol use in the EU

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

UK bowel cancer care outcomes: A comparison with Europe

Screening for Cervical Cancer in Europe

REPORT ON LAWS AND RECOMMENDATIONS ON DENTAL MERCURY MANAGEMENT IN THE EU

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

Trends in injecting drug use in Europe

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Primary and secondary prevention of sudden cardiac death in emerging economies

Review of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes

Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci. Infectious Diseases & Immunity

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

Overall survival: 1 st line therapy

EFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

Alcohol Prevention Day

Present and potential perspectives for information on alcohol use in the EU

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

A phylodynamic analysis of HIV-1 in Germany

EURO POLIO PAGE Data as of 04 October 2005 (Week 38)

Overview of European Consumption Databases

Highly pathogenic avian influenza "The Epidemic" Regionalisation in the European Union

PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY

Table 7.1 Summary information for lung cancer in Ireland,

Transcription:

Outcome of proficiency test on EIA serology Anses Dozulé Laboratory for equine diseases VIPARE unit Delphine Gaudaire

EIA PT GENERAL INFORMATION AIM OF THE PT Detect EIA antibodies: using Agar Gel Immuno-Diffusion Test (AGID test) as described in the OIE manual Chapter 2.5.6 using Enzyme ImmunoSorbent Assay (ELISA) 10th Workshops of equine diseases - Delphine GAUDAIRE 2

EIA PT GENERAL INFORMATION INFORMATION TO 34 LABS Information sent by e-mail on May 17 th, 2018 SCHEDULE OF THE BOTH EIA PT Samples sent on June 12 th, 2018 Results due on July 6 th, 2018 Each participant received an outcome of the PT by e-mail: EIA AGID PT: September 3 rd, 2018 EIA ELISA PT: September 4 th, 2018 Official report will be sent to each lab by the end of September 10th Workshops of equine diseases - Delphine GAUDAIRE 3

Lab codification: EIA PT CODIFICATION EIA AGID lab code EIA ELISA lab code Participant 1 18-A 18-G Participant 2 18-B / Participant 3 18-C 18-D Codification of samples : Lab code Sample # 1 2 3 4 5 6 7 8.. 20 21 22 23 24 18-A 645 267 288 426 95 656 632 691. 816 758 690 538 194 18-B 721 397 891 384 14 959 58 256. 572 533 794 191 958 18-C 407 569 893 172 623 776 355 405. 772 108 187 300 446 10th Workshops of equine diseases - Delphine GAUDAIRE 4

EIA PT sample validation Validation of each lyophilized serum: Homogeneity 25 tested vials in 1 assay (FD ISO GUIDE 35) using ELISA Reproducibility 3 vials tested in three independent AGID tests AGID 1 AGID 2 AGID 3 10th Workshops of equine diseases - Delphine GAUDAIRE 5

EIA PT sample validation Stability Short-term stability (stability after reconstitution): 3 days at room temperature 1 week at +2-8 C 1 month at -20 C Long-term stability (accelerated conditions): 3 weeks at +30 C before reconstitution Homogeneity, reproducibility and stability have been validated for all the sera produced for the both PT 10th Workshops of equine diseases - Delphine GAUDAIRE 6

Outcome of EIA AGID PT 10th Workshops of equine diseases - Delphine GAUDAIRE 7

EIA AGID PT GENERAL INFORMATION EIA AGID PT nb of participants: 32 (26 NRLs) EU COUNTRIES AUSTRIA BELGIUM BULGARIA CROATIA CZECH REPUBLIC CYPRUS DENMARK ESTONIA FINLAND FRANCE GERMANY GREECE HUNGARY IRELAND ITALY LATVIA LITHUANIA LUXEMBOURG MALTE POLAND PORTUGAL ROMANIA SLOVAKIA SLOVENIA SPAIN SWEDEN THE NETHERLANDS UNITED KINGDOM EIA AGID PT 2010 2014 2018 21/26 24/28 26/28 10th Workshops of equine diseases - Delphine GAUDAIRE 8

EIA AGID PT samples Preparation of 9 batches of serum Mix of 2 negative sera 1 naturally infected horse 2 experimentally infected horses Serum 1 Serum 2 Sera 3 to 8 Serum 9 Lyophilization 10th Workshops of equine diseases - Delphine GAUDAIRE 9

24 samples/panel to be analyzed by AGID test : Serum # Sample # Expected result 1 1 to 12 Negative 2 13 to 14 Positive 3 15 to 16 Positive 4 17 Positive 5 18 Positive 6 19 to 20 Positive 7 23 Positive 8 24 Positive 9 21 to 22 Positive 12 negative samples 12 positive samples EIA AGID PT samples 4 strong positive: sample# 15-16-17-23 3 medium positive: sample# 18-21-22 5 weak positive: sample# 13-14-19-20-24 10th Workshops of equine diseases - Delphine GAUDAIRE 10

EIA AGID PT results Criteria to evaluate the performance of each participant : All negative samples should be found as such All positive samples should be found as such Only one mistake out of 24 samples was accepted 10th Workshops of equine diseases - Delphine GAUDAIRE 11

Sample # EIA AGID PT results 12 11 10 9 8 7 6 5 4 3 2 1 0 Negative samples Lab code 13 14 15 16 17 18 19 20 21 22 23 24 100% of participants obtained satisfactory results Each laboratory exhibited a very good specificity 10th Workshops of equine diseases - Delphine GAUDAIRE 12

Sample # 12 11 10 9 8 7 6 5 4 3 2 1 0 EIA AGID PT results Positive samples Serum # 8 7 9 6 5 4 3 2 Lab code 1 2 3 4 5 6 7 8 9 10 11 12 11 out of 372 positive samples have been analyzed as negative (specificity: 97%) 3 laboratories failed to detect positive samples 29 out of 32 participants obtained satisfactory results 10th Workshops of equine diseases - Delphine GAUDAIRE 13

% % EIA AGID PT results 100 80 60 40 20 0 Negative Strong positive Medium positive Weak positive % satisfactory result % unsatisfactory result Intea Home made VMRD Idvet Idexx 1 3 7 8 13 0 5 10 15 Nb 100 % of labs that obtained satisfactory results according to the kit used 62,5 100 100 100 Idexx Idvet VMRD Home made INTEA Manufacturer Unsatisfactory results are not in relation with the kit used 10th Workshops of equine diseases - Delphine GAUDAIRE 14

EIA AGID PT conclusion 29 out of the 32 labs obtained satisfactory results European NRL network exhibited a very good specificity 26/26 detected all negative samples The sensitivity of European NRL network is 88,5% 23/26 European NRL detected all positive samples 3 labs need to improve their sensitivity to detect all positive samples (especially weak positive sample) Training session will be organize by the EU-NRL 10th Workshops of equine diseases - Delphine GAUDAIRE 15

Outcome of EIA ELISA PT 10th Workshops of equine diseases - Delphine GAUDAIRE 16

EIA ELISA PT GENERAL INFORMATION EIA AGID PT nb of participants: 23 EU COUNTRIES AUSTRIA BELGIUM BULGARIA CROATIA CZECH REPUBLIC CYPRUS DENMARK ESTONIA FINLAND FRANCE GERMANY GREECE HUNGARY IRELAND ITALY LATVIA LITHUANIA LUXEMBOURG MALTE POLAND PORTUGAL ROMANIA SLOVAKIA SLOVENIA SPAIN SWEDEN THE NETHERLANDS UNITED KINGDOM EIA ELISA PT 2018 19/26 10th Workshops of equine diseases - Delphine GAUDAIRE 17

EIA ELISA PT samples Preparation of 9 batches of serum Mix of 2 negative sera 1 naturally infected horse 2 experimentally infected horses Serum 1 Sera 2 to 3 Sera 4 to 6 Sera 7 to 9 Lyophilization 10th Workshops of equine diseases - Delphine GAUDAIRE 18

EIA ELISA PT samples 24 samples/panel to be analyzed by ELISA: Serum # Sample # Expected result 1 1 to 8 Negative 2 9 to 11 Positive 3 12 to 14 Positive 4 15 Positive 5 16 to 18 Positive 7 19 Positive 6 20 to 21 Positive 8 22 Positive 9 23 to 24 Positive 8 negative samples 16 positive samples 10th Workshops of equine diseases - Delphine GAUDAIRE 19

EIA ELISA PT results Criteria to evaluate the performance of each participant : All negative samples should be analyzed as such All positive samples should be analyzed as such 10th Workshops of equine diseases - Delphine GAUDAIRE 20

Samples # 8 7 6 5 4 3 2 1 0 EIA ELISA PT results Negative samples Lab code 1 2 3 4 5 6 7 8 100% of participants obtained satisfactory results Each laboratory exhibited a very good specificity 10th Workshops of equine diseases - Delphine GAUDAIRE 21

Sample # 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 EIA ELISA PT results Positive samples Serum # 9 8 7 6 5 4 3 2 Lab code 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 2 laboratories failed to detect positive samples (sensitivity: 98,4%) 21 out of 23 labs obtained satisfactory results 10th Workshops of equine diseases - Delphine GAUDAIRE 22

% EIA ELISA PT results Synbiotics Home made VMRD INGENASA 1 1 2 3 100 100 100 100 67 33 100 Idvet 9 Idexx 9 0 5 10 Nb % satisfactory results % unsatisfactory results Lab code 18-P and 18-S failed to detect the same serum (# 5) 3 labs used INGENASA kits and 2 out of 3 failed to detect the positive serum 5 10th Workshops of equine diseases - Delphine GAUDAIRE 23

EIA ELISA PT results 21 out of the 23 labs obtained satisfactory results European NRL network exhibited a very good specificity The sensitivity of European NRL network is 89,5% 17 out of 19 European NRL detected all positive samples 2 labs failed to detect all positive samples of the ELISA PT 10th Workshops of equine diseases - Delphine GAUDAIRE 24

Acknowledgments Aymeric HANS Alexandre DESHIERE Laurent HÉBERT Fanny LECOUTURIER Anthony MADELINE Jessy VANDEKERKHOVE 10 th Workshops of equine diseases - Delphine GAUDAIRE 24

Thank for your attention 10th Workshops of equine diseases - Delphine GAUDAIRE 26